Background {#Sec1}
==========

Nasopharyngeal carcinoma (NPC) shows a distinct difference in geographical distribution globally. Although it is rare in most countries worldwide, with an incidence of less than 1 per 100,000 person-years, it is common in southern China, with an estimated incidence rate of more than 20 per 100,000 person-years \[[@CR1], [@CR2]\]. Among the proposed etiological factors for NPC, including genetics, environmental factors, and life style, Epstein--Barr virus (EBV) infection is considered an important risk factor for NPC initiation and progression \[[@CR3], [@CR4]\]. EBV DNA is consistently detected in all NPC tissues \[[@CR5], [@CR6]\]. Anti-EBV antibody titers can be elevated for several years before clinical evidence of NPC appears, and they have been used for NPC screening in NPC endemic regions \[[@CR7]--[@CR9]\]. Additionally, the circulating EBV DNA load has been used as a prognostic marker for monitoring patients after NPC treatment \[[@CR10], [@CR11]\]. However, the fact that approximately 95% of the world's population sustains an asymptomatic EBV infection with a relatively low NPC incidence suggests the involvement of other synergistic risk factors in the process of carcinogenesis in nasopharyngeal epithelial cells, such as genetic susceptibility, smoking, preserved food consumption, and inflammation \[[@CR12]--[@CR14]\].

NPC is characterized by a heavy infiltration of nonmalignant lymphocytes, suggesting that inflammation might be an important co-factor for this cancer. During inflammation, highly reactive nitrogen and oxygen species can be released from inflammatory cells, resulting in permanent genomic alterations in the nasopharyngeal epithelium. These genetic and epigenetic events may facilitate the infection of nasopharyngeal epithelial cells by EBV \[[@CR15]--[@CR17]\]. Inflammation can also disturb overall immune competence, which could promote latent EBV to enter lytic cycles \[[@CR18], [@CR19]\].

Measuring circulating levels of inflammatory markers can help to evaluate the relationship of cancer with chronic inflammation. Previous studies \[[@CR20]--[@CR22]\] of inflammatory markers in NPC have detected a few inflammatory markers, such as interleukin (IL)-6, IL-1, IL-10, tumor necrosis factor (TNF)-alpha, and vascular endothelial growth factor (VEGF). However, all these studies were retrospective and could not infer the state of the circulating cytokines prior to the development of NPC \[[@CR20]--[@CR23]\]. Therefore, comprehensive prospective studies are still needed to clarify the relationship between the immune status of precancerous lesions and NPC.

Our previous studies using multiplex assay platforms, which enable the simultaneous evaluation of many circulating cytokines in small amounts of serum, have shown acceptable performance in liver cancer \[[@CR24]\] and colorectal cancer cohorts \[[@CR25]\]. Therefore, the present study applied this technology to explore the relationship between circulating cytokine levels and risk of subsequent NPC development using a hospital-based case--control study, followed by a nested case--control design in a population-based screening trial in Sihui, China \[[@CR26]\]. We also analyzed whether a combination of serum cytokines and EBV could further increase the risk of NPC.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

### Case--control study {#Sec4}

The serum samples of 150 patients with NPC and 150 healthy controls undergoing routine health examinations were consecutively collected from the serum bank of Sun Yat-sen University Cancer Center (SYSUCC). The patients were selected based on the following criteria: (i) Cantonese NPC patients with histologically proven NPC who had not undergone any treatment; (ii) aged 30--59 years old; (iii) lacked any severe inflammation, immune system disease, or diabetes; and (iv) had serum samples collected before treatment. These Cantonese examinees were frequency matched to patients in the same hospital by gender, age group (≤ 40 and \> 40 years), and year of blood collection using a 1:1 ratio. The TNM staging for patients with NPC was defined according to the staging system described in the seventh edition of Union for International Cancer Control (UICC), and NPCs were classified by the World Health Organization (WHO) classification \[[@CR27]\]. All diagnoses of NPC were proven by biopsy.

### Nested case--control study {#Sec5}

A nested case--control study was conducted complementary to the case--control study. Subjects in the nested case--control study were recruited within an ongoing cluster-randomized NPC screening trial in Sihui, southern China, from May 30, 2008 \[[@CR28]\]. In brief, two EBV-related serologic immunoglobulin A antibodies against capsid antigen (VCA/IgA) and EBV nuclear antigen-1 (EBNA1)/IgA were used as screening markers. The inclusion criteria were: (i) Cantonese patients who were aged 30--59 years, (ii) lack of any recorded history of NPC, and (iii) in good physical condition and mental health. The exclusion criteria were: (i) patients who had severe cardiovascular, liver, or kidney diseases or immune deficiency disease, and (ii) patients with prevalent NPC. Eligible participants were invited to donate 6 mL of blood for serological tests; their basic information was collected. Blood samples were allowed to clot at room temperature, followed by centrifugation at 2000×*g* for 10 min. The serum samples were then aliquoted and stored at − 80 °C. No more than two freeze--thaw cycles were allowed for each serum sample. According to the baseline serological results, the participants were advised to undergo nasopharynx endoscopic examinations or follow-up at different intervals \[[@CR26], [@CR29]\]. Controls free of cancer were individually matched at a 2:1 ratio to case patients based on age (varying within 1 year), gender, year of enrollment, and follow-up years. All subjects gave written informed consent, and human subject approval was obtained from the Institutional Review Board of SYSUCC (No. YP2009051). The data from this study have been uploaded onto the Research Data Deposit public platform (<http://www.researchdata.org.cn>), with the approval RDD number RDDA2017000189.

Serum cytokine analysis {#Sec6}
-----------------------

The serum levels of 33 immune and inflammation markers in 25 µL of baseline serum specimens in the case--control study were measured using the human cytokine/chemokine magnetic bead panel (Millipore, Billerica, MA, USA). The 33 cytokine markers included in this panel are listed in Additional file [1](#MOESM1){ref-type="media"}: Table S1. The serum samples were blinded to the measurer and assayed in duplicate, and the average concentrations were calculated for each cytokine. These markers were evaluated for the performance and reproducibility of multiplexed immune/inflammation assays on the basis of a recent methodological study \[[@CR30]\]. The concentrations of markers in the serum samples were measured according to the manufacturer's standard protocol and eventually analyzed using the Luminex 200 analyzer (Luminex, Austin, TX, USA). The concentrations were calculated with a standard curve (ranging from 3.2 to 10,000 pg/mL) made by five-fold dilutions of the human cytokine reconstituted standard in the provided assay buffer. The serum samples were randomly assigned to plates to avoid assay bias. The coefficients of variation (CVs) and intraclass correlation coefficients (ICCs) of quality controls provided by the manufacturer were computed to evaluate the reproducibility of assays.

Detection of anti-EBV antibodies {#Sec7}
--------------------------------

The levels of EBNA1/IgA were detected using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Zhongshan Bio-Tech Company, Zhongshan, China) for all samples in this study. The relative optical density (rOD) was calculated by dividing the optical density of one sample by that of a reference control, and the positive criteria was set as 1.5. The ICCs and their 95% confidence intervals (CIs) of quality controls were calculated to ensure the reliability of the serological results.

Statistical analysis {#Sec8}
--------------------

Samples with values below the assay lower limit of detection were assigned a value of half the lower limit of detection. Marker levels were categorized into groups on the basis of the proportion of samples with measurements above the lower limit of detection as follows \[[@CR31], [@CR32]\]: Markers with more than 75% of measurements above the lower limit of detection were categorized into quartiles on the basis of the distribution among controls, markers with 50%--75% of measurements above the lower limit of detection were categorized into three groups (lower than lower limit of detection, lower than median detectable level among controls, or higher than median detectable level), and markers with less than 50% of measurements above the lower limit of detection were categorized into two groups (lower than lower limit of detection and detectable level). Tests for trend were conducted for markers with three or more categories by modeling the intracategory medians as a continuous parameter. Differences in marker levels between patients with NPC and healthy controls were determined using the Wilcoxon rank-sum test. Unconditional logistic regression models were used to compute odds ratios (ORs) and 95% CIs relating the serum marker concentration to the risk of NPC in the case--control study, and conditional logistic regression models were used similarly for the nested case--control study following adjustment for age, gender, salted fish consumption, family history, and EBNA1/IgA. The case patients in the nested case--control were stratified into patients who were diagnosed within 1 year and patients who were diagnosed more than 1 year after the blood was collected. Potential interactions between EBV infection and these immune cytokine markers were assessed using the likelihood ratio test. Correlation between cytokine levels was performed on original serum cytokine levels, using the Spearman correlation coefficient. All tests of statistical significance were two sided at *α* = 0.05. Analyses were performed using SAS version 9.2 (SAS Inc, Cary, NC, USA).

Results {#Sec9}
=======

Characteristics of participants in the case--control study and the nested case--control study {#Sec10}
---------------------------------------------------------------------------------------------

The distributions of patients and controls by selected demographic and clinicopathologic characteristics are summarized in Table [1](#Tab1){ref-type="table"}. In both case--control studies, patients with NPC and controls had similar gender and age distributions. The average ages of patients with NPC and healthy controls were 45.7 vs. 45.7 years old, respectively, in the case--control study, and 47.8 vs. 47.8 years old, respectively, in nested case--control study.Table 1Nasopharyngeal carcinoma (NPC) and healthy control patient characteristics in the case--control and nested case--control studiesCharacteristicCase--control study \[cases (%)\]Nested case--control study \[cases (%)\]NPC patientsControls*P* valueNPC patientsControls*P* valueTotal15015060120Gender1.0001.000 Male130 (86.7)130 (86.7)35 (58.3)70 (58.3) Female20 (13.3)20 (13.3)25 (41.7)50 (41.7)WHO histological classification I5 (3.3)NA2 (3.3)NA II3 (2.0)NA1 (1.7)NA III142 (94.7)NA57 (95.0)NAClinical stage Early (I + II)51 (34.0)NA35 (60.3)NA Advanced (III + IV)99 (66.0)NA23 (39.7)NA Unknown0NA2NAEBNA1/IgA Seronegative52 (34.7)120 (80.0)\< 0.00128 (46.7)115 (95.8)\< 0.001 Seropositive98 (65.3)30 (20.0)32 (53.3)5 (4.2)*NA* not applicable, *NPC* nasopharyngeal carcinoma, *I* squamous cell carcinoma, *II* differentiated nonkeratinizing carcinoma, *III* undifferentiated carcinoma, *Early* clinical stage I and clinical stage II, *Advanced* clinical stage III and clinical stage IV, *EBNA1/IgA* anti-Epstein--Barr virus nuclear antigen-1 immunoglobulin A antibody, *seronegative* the relative optical density (rOD) of the sample was \< 1.5, *seropositive* the rOD of the sample was ≥ 1.5

In the nested case--control study, NPC cases and controls were selected from an NPC screening cohort in Sihui. In brief, 11,993 individuals were recruited into the NPC screening program. As of December 31, 2015, 63 NPCs were diagnosed in the screened population. Due to three of these patients lacking baseline blood samples, a total of 60 patients with NPC and 120 controls were included in the nested case--control study.

According to available information on cancer staging, the most (\> 95%) pathological tumor type in these two studies was nonkeratinizing carcinoma, and the levels of EBNA1/IgA were clearly higher in patients with NPC than in controls (65.3% vs. 20.0% in the case--control study and 53.3% vs. 4.2% in the nested case--control study). However, the nested case--control study had more early-stage patients (60.3%) than the case--control study (34.0%).

Measurement qualities of serum cytokines and anti-EBV antibodies {#Sec11}
----------------------------------------------------------------

In the case--control study, the 19 cytokine markers with less than 30% of sample measurements above the lower limit of detection were excluded from the analysis. After this exclusion, 14 markers were included in the statistical analysis for each of the two case--control studies. The CVs of the 14 detectable cytokine markers were between 15.6% and 27.9% in the case--control study. For the nested case--control study, the CVs were between 5.1% and 15.5%. The ICCs of the 14 markers included in further analysis for both the case--control study and nested case--control study were all above 0.90 (Additional file [1](#MOESM1){ref-type="media"}: Table S1). The ICC of EBNA1/IgA was 0.99 (95% CI 0.91--0.99) in the case--control study and 0.98 (95% CI 0.96--0.99) in the nested case--control study.

Association of serum cytokines with the risk of NPC {#Sec12}
---------------------------------------------------

In the case--control study, the median levels of macrophage inflammatory protein (MIP)-1α, MIP-1β, epidermal growth factor (EGF), granulocyte colony-stimulating factor (GCSF), fractalkine, growth-regulated oncogene (GRO), and IL-1α were all significantly lower (*P *\< 0.05) in patients with NPCs than in controls. However, only MIP-1β had a similar result (*P *\< 0.05) in the nested case--control study. In contrast, the median level of monocyte chemotactic protein 1 (MCP-1) in the case--control study was significantly higher in patients with NPC than in controls (Table [2](#Tab2){ref-type="table"}).Table 2The levels of 14 markers in nasopharyngeal carcinoma (NPC) patients and control subjectsMarkerCase--control studyNested case--control studyNPC patients (pg/mL)Controls (pg/mL)*P*NPC patients (pg/mL)Controls (pg/mL)*P*MedianP~25~P~75~MedianP~25~P~75~MedianP~25~P~75~MedianP~25~P~75~EGF209.3125.8327.1392.5238.9594.4\< 0.001442.3274.5583.5477.0333.4629.00.26Eotaxin126.695.4174.4143.6106.2186.90.098140.096.1195.4139.196.0212.00.86GCSF6.51.615.615.64.350.9\< 0.00122.87.640.618.65.831.20.13Fractalkine11.411.411.459.211.4211.2\< 0.00192.911.4547.292.911.4380.40.76IFN-γ6.01.625.510.03.624.50.0795.81.611.64.91.611.70.87GRO940.6731.41272.01406.0964.62309.5\< 0.0011926.01346.54808.51615.51209.52652.50.13MDC861.3669.81122.0894.4590.71179.00.89883.3625.11248.5814.0628.01122.00.55IL-1α4.74.74.74.74.768.8\< 0.0014.74.724.44.74.798.00.08IL-71.61.67.33.21.611.90.113.31.65.31.61.63.70.035IL-820.47.839.816.47.534.00.4858.87.3269.6108.213.3380.40.106MCP-1465.2348.3598.1400.0232.9568.80.004617.3400.0789.0598.1450.8788.80.38MIP-1α1.61.666.529.01.695.40.02325.91.657.032.64.3114.50.105MIP-1β51.525.882.662.632.0102.20.03669.831.2116.788.543.8157.80.045VEGF297.7129.0594.4279.6129.0459.30.46218.879.0357.2188.288.5364.10.73*NPC* nasopharyngeal carcinoma, *P* computed using a Wilcoxon rank-sum test, *EGF* epidermal growth factor, *GCSF* granulocyte colony-stimulating factor, *IFN-γ* interferon gamma, *GRO* growth-regulated oncogene, *MDC* macrophage-derived chemokine, *IL-1α* interleukin-1 alpha, *IL-7* interleukin-7, *IL-8* interleukin-8, *MCP-1* monocyte chemotactic protein-1, *MIP-1α* macrophage inflammatory protein-1 alpha, *MIP-1β* macrophage inflammatory protein-1 beta, *VEGF* vascular endothelial growth factor

The results of multivariable logistic regression analyses between serum cytokine levels and risk of NPC are summarized in Table [3](#Tab3){ref-type="table"}. After adjustment for age, sex, salted fish consumption, family history, and EBNA1/IgA, both MIP-1α and MIP-1β remained significantly different between cases and controls in both studies. The levels of MIP-1α and MIP-1β in the highest category were associated with a statistically significantly decreased risk of NPC compared with those in category 1, both in the case--control study (MIP-1α: OR = 0.49, 95% CI = 0.26--0.95; MIP-1β: OR = 0.47, 95% CI = 0.22--1.00) and in the nested case--control study (MIP-1α: OR = 0.13, 95% CI = 0.03--0.62; MIP-1β: OR = 0.20, 95% CI = 0.04--0.94). In the case--control study, the participants with serum EGF, GCSF, fractalkine, GRO, IL-1α, and IL-7 levels in the highest categories were significantly associated with a decreased risk of NPC compared with those in the lowest categories, whereas MCP-1 was significantly associated with the increased risk of NPC, after adjustment for age, sex, salted fish consumption, family history, and EBNA1/IgA. However, the associations of these markers with the risk of NPC development could not be verified in the nested case--control study.Table 3Serum cytokine marker associations with nasopharyngeal carcinoma (NPC) in the case--control and nested case--control studiesMarkerCase--control study (cases)^a^Nested case--control study (cases)NPC patientsControlsOR~1~ (95% CI)OR~2~ (95% CI)OR~3~ (95% CI)NPC patientsControlsOR~1~ (95% CI)OR~2~ (95% CI)OR~3~ (95% CI)EGF Category 18437ReferenceReferenceReference1930ReferenceReferenceReference Category 238370.45 (0.25--0.82)0.40 (0.20--0.78)0.39 (0.20--0.76)17330.83 (0.35--1.95)1.18 (0.31--4.55)1.17 (0.28--4.85) Category 320370.24 (0.12--0.46)0.29 (0.14--0.60)0.30 (0.14--0.62)11280.63 (0.26--1.54)0.85 (0.24--2.92)0.87 (0.22--3.43) Category 48370.10 (0.04--0.22)0.09 (0.04--0.24)0.09 (0.04--0.24)13290.71 (0.29--1.73)0.46 (0.11--1.90)0.62 (0.14--2.77)*P* ~trend~\< 0.001\< 0.001\< 0.0010.3830.1990.434Eotaxin Category 15137ReferenceReferenceReference1530ReferenceReferenceReference Category 237370.73 (0.39--1.35)0.59 (0.29--1.19)0.62 (0.30--1.25)15310.97 (0.43--2.21)1.08 (0.35--3.30)1.01 (0.31--3.21) Category 332370.63 (0.33--1.18)0.60 (0.29--1.22)0.62 (0.30--1.27)18291.24 (0.53--2.89)1.22 (0.36--4.12)1.05 (0.29--3.84) Category 430370.59 (0.31--1.12)0.50 (0.24--1.03)0.53 (0.25--1.10)12300.80 (0.32--2.01)1.07 (0.34--3.34)1.06 (0.30--3.74)*P* ~trend~0.1010.0720.1030.7330.8940.921GCSF Category 15739ReferenceReferenceReference1431ReferenceReferenceReference Category 252311.15 (0.63--2.10)1.29 (0.65--2.54)1.36 (0.68--2.73)11330.68 (0.26--1.81)1.05 (0.25--4.42)1.14 (0.26--5.08) Category 323350.45 (0.23--0.88)0.39 (0.18--0.84)0.39 (0.18--0.86)13241.21 (0.51--2.88)2.47 (0.70--8.71)1.91 (0.50--7.38) Category 411340.22 (0.10--0.49)0.24 (0.10--0.59)0.24 (0.10--0.58)21291.57 (0.65--3.80)2.33 (0.66--8.22)2.07 (0.53--8.02)*P* ~trend~\< 0.001\< 0.001\< 0.0010.1300.1040.232Fractalkine Category 110560ReferenceReferenceReference1939ReferenceReferenceReference Category 233830.23 (0.14--0.38)0.25 (0.14--0.42)0.25 (0.14--0.45)13320.79 (0.33--1.91)1.47 (0.40--5.34)1.23 (0.40--5.34) Category 319321.44 (0.65--3.17)2.52 (0.75--8.50)3.44 (0.49--21.57)*P* ~trend~0.2440.1450.119IFN-γ Category 15333ReferenceReferenceReference1842ReferenceReferenceReference Category 241530.48 (0.27--0.87)0.46 (0.23--0.90)0.47 (0.24--0.92)21371.34 (0.63--2.86)1.70 (0.53--5.45)1.82 (0.52--6.32) Category 346590.49 (0.27--0.87)0.48 (0.25--0.92)0.50 (0.26--0.96)15371.06 (0.46--2.42)2.31 (0.69--7.68)2.50 (0.68--9.18)*P* ~trend~0.0920.1430.1790.9660.1990.202GRO Category 18234ReferenceReferenceReference829ReferenceReferenceReference Category 244370.49 (0.27--0.89)0.44 (0.23--0.86)0.44 (0.23--0.86)15311.62 (0.61--4.31)0.90 (0.23--3.48)0.63 (0.14--2.84) Category 318310.24 (0.12--0.49)0.25 (0.11--0.54)0.26 (0.12--0.57)12301.22 (0.41--3.65)0.52 (0.12--2.34)0.36 (0.07--1.76) Category 46340.07 (0.03--0.19)0.08 (0.03--0.21)0.08 (0.03--0.21)18252.40 (0.96--6.04)1.69 (0.50--5.76)1.01 (0.26--3.87)*P* ~trend~\< 0.001\< 0.001\< 0.0010.0640.2290.622MDC Category 12738ReferenceReferenceReference1733ReferenceReferenceReference Category 249361.92 (1.00--3.69)2.27 (1.08--4.75)2.21 (1.06--4.63)6270.46 (0.16--1.33)0.28 (0.06--1.18)0.29 (0.07--1.22) Category 343381.59 (0.82--3.08)1.40 (0.67--2.96)1.46 (0.69--3.07)18311.17 (0.51--2.72)1.15 (0.35--3.76)1.29 (0.36--4.59) Category 430371.14 (0.57--2.27)1.22 (0.56--2.65)1.24 (0.57--2.71)19291.36 (0.55--3.36)1.59 (0.45--5.69)1.34 (0.35--5.06)*P* ~trend~0.8600.7940.9020.2610.2640.448IL-1α Category 112577ReferenceReferenceReference4073ReferenceReferenceReference Category 212510.15 (0.07--0.29)0.17 (0.08--0.37)0.17 (0.08--0.37)11360.73 (0.34--1.56)0.97 (0.38--2.48)1.17 (0.43--3.17)IL-7 Category 17669ReferenceReferenceReference2982ReferenceReferenceReference Category 248371.18 (0.69--2.02)0.85 (0.46--1.58)0.85 (0.46--1.60)26352.01 (1.03--3.93)1.32 (0.56--3.12)0.99 (0.39--2.51) Category 319370.47 (0.25--0.89)0.40 (0.19--0.83)0.40 (0.19--0.83)*P* ~trend~0.0180.0140.014IL-8 Category 13535ReferenceReferenceReference1929ReferenceReferenceReference Category 230370.81 (0.41--1.59)0.66 (0.31--1.41)0.68 (0.32--1.45)20291.05 (0.46--2.42)1.08 (0.29--3.92)1.41 (0.36--5.53) Category 338331.15 (0.60--2.23)0.66 (0.31--1.43)0.70 (0.32--1.52)8270.38 (0.13--1.09)0.18 (0.04--0.96)0.18 (0.03--1.08) Category 445341.32 (0.69--2.53)1.05 (0.51--2.18)1.09 (0.52--2.28)12280.55 (0.21--1.44)0.24 (0.04--1.33)0.26 (0.04--1.83)*P* ~trend~0.2200.4610.4120.1690.0860.167MCP-1 Category 11138ReferenceReferenceReference2230ReferenceReferenceReference Category 245374.20 (1.89--9.35)2.89 (1.20--6.92)2.84 (1.19--6.80)6290.17 (0.04--0.65)0.28 (0.06--1.35)0.36 (0.07--1.94) Category 348394.25 (1.92--9.40)3.45 (1.46--8.18)3.87 (1.62--9.25)17300.70 (0.30--1.68)0.52 (0.15--1.77)0.56 (0.16--1.99) Category 446364.41 (1.98--9.83)3.15 (1.32--7.56)3.41 (1.42--8.19)13290.61 (0.24--1.53)0.48 (0.14--1.71)0.45 (0.12--1.73)*P* ~trend~0.0060.0430.0230.6180.3750.279MIP-1α Category 18366ReferenceReferenceReference2031ReferenceReferenceReference Category 234420.64 (0.37--1.12)0.58 (0.31--1.09)0.60 (0.32--1.14)14290.81 (0.35--1.89)0.92 (0.30--2.87)0.73 (0.25--2.13) Category 333420.63 (0.36--1.09)0.48 (0.25--0.92)0.49 (0.26--0.95)21301.15 (0.47--2.83)1.33 (0.35--5.05)1.24 (0.47--3.26) Category 45300.29 (0.10--0.85)0.16 (0.03--0.98)0.13 (0.03--0.62)*P* ~trend~0.1320.0340.0450.0200.0250.009MIP-1β Category 14737ReferenceReferenceReference2130ReferenceReferenceReference Category 243370.92 (0.49--1.69)0.83 (0.41--1.65)0.85 (0.42--1.70)17300.84 (0.38--1.85)0.67 (0.23--1.96)0.62 (0.20--1.88) Category 335370.75 (0.40--1.40)0.69 (0.34--1.40)0.69 (0.34--1.41)12300.78 (0.34--1.76)0.63 (0.20--2.03)0.55 (0.15--2.02) Category 423370.49 (0.25--0.96)0.45 (0.21--0.97)0.47 (0.22--1.00)10290.39 (0.16--0.99)0.23 (0.06--0.91)0.20 (0.04--0.94)*P* ~trend~0.0290.0340.0410.0480.0370.043VEGF Category 13539ReferenceReferenceReference1531ReferenceReferenceReference Category 234341.11 (0.58--2.15)0.88 (0.41--1.87)0.81 (0.38--1.74)8290.62 (0.22--1.75)0.46 (0.10--2.08)0.42 (0.09--1.99) Category 327360.84 (0.43--1.64)0.85 (0.40--1.83)0.84 (0.40--1.81)23301.61 (0.65--3.96)0.73 (0.18--2.98)0.58 (0.13--2.61) Category 444361.36 (0.72--2.57)1.25 (0.61--2.57)1.26 (0.61--2.59)13290.97 (0.37--2.51)0.78 (0.24--2.57)0.67 (0.18--2.48)*P* ~trend~0.3660.4330.3910.8210.9260.784*NPC* nasopharyngeal carcinoma, *OR*~*1*~ odds ratio computed using logistic regression adjusted for gender and age, *OR*~*2*~ computed using logistic regression adjusted for gender, age, and anti-Epstein--Barr virus nuclear antigen-1 immunoglobulin A antibody (EBNA1/IgA), *OR*~*3*~ computed using logistic regression adjusted for gender, age, salted fish consumption, family history, and EBNA1/IgA, *CI* confidence interval, *Category 1* lower than the lower limit of detection among controls with less than three groups or the first quartile with four groups, *Category 2* detectable level with two groups, lower than median detectable level among controls with three groups, or in the second quartile with four groups, *Category 3* higher than the median detectable level with three groups or in the third quartile with four groups, *Category 4* in the fourth quartile among controls, *P*~*trend*~ computed using Wald statistic of regression model parameters for marker intracategory medians modeled as a continuous variable, *EGF* epidermal growth factor, *GCSF* granulocyte colony-stimulating factor, *IFN-γ* interferon gamma, *GRO* growth-regulated oncogene, *MDC* macrophage-derived chemokine, *IL-1α* interleukin-1 alpha, *IL-7* interleukin-7, *IL-8* interleukin-8, *MCP-1* monocyte chemotactic protein-1, *MIP-1α* macrophage inflammatory protein-1 alpha, *MIP-1β* macrophage inflammatory protein-1 beta, *VEGF* vascular endothelial growth factor^a^Samples were excluded from the analysis process for the corresponding marker if the marker serum level of each sample exceeded three times the quartile range above the median

Associations between serum MIP-1α and MIP-1β and the subsequent diagnosis of NPC in the nested case--control study {#Sec13}
------------------------------------------------------------------------------------------------------------------

To remove the potential confounding factor of subclinical malignancies that might change the circulating MIP-1α and MIP-1β levels, we excluded NPC cases diagnosed within 1 year after baseline blood collection in the nested case--control study. In the subset of case patients who were diagnosed more than 1 year after blood collection, the levels of MIP-1α and MIP-1β in category 4 were still statistically significantly associated with a decreased risk of NPC compared with those in the reference category after adjustment for age, sex, salted fish consumption, family history, and EBNA1/IgA (MIP-1α: OR = 0.09, 95% CI = 0.01--0.82, *P*~trend~ = 0.036; MIP-1β: OR = 0.12, 95% CI = 0.01--0.94, *P*~trend~ = 0.047) (Table [4](#Tab4){ref-type="table"}).Table 4Associations of macrophage inflammatory protein (MIP)-1α and MIP-1β serum levels with nasopharyngeal carcinoma (NPC) risk in the nested case--control study by the time interval between blood collection and diagnosisMarker^a^Cases diagnosed within 1 year after blood collectionCases diagnosed more than 1 year after blood collectionNPCsControlsOR~1~ (95% CI)OR~2~ (95% CI)OR~3~ (95% CI)NPCsControlsOR~1~ (95% CI)OR~2~ (95% CI)OR~3~ (95% CI)MIP-1α Category 1814ReferenceReferenceReference1217ReferenceReferenceReference Category 2490.70 (0.18--2.81)2.68 (0.20--35.6)1.03 (0.14--7.60)10200.81 (0.28--2.36)0.68 (0.18--2.61)0.59 (0.15--2.37) Category 39150.94 (0.21--4.18)10.14 (0.58--177)1.76 (0.33--9.51)12151.13 (0.36--3.54)0.62 (0.12--3.29)1.21 (0.31--4.70) Category 42100.32 (0.05--1.86)0.80 (0.06--10.2)0.10 (0.01--2.39)2200.16 (0.03--0.81)0.07 (0.01--0.82)0.09 (0.01--0.82)*P* ~trend~0.4620.4500.3120.0200.0320.036MIP-1β Category 1613ReferenceReferenceReference1517ReferenceReferenceReference Category 27131.16 (0.31--4.34)1.28 (0.20--8.42)1.79 (0.22--14.7)10170.72 (0.26--2.00)0.41 (0.10--1.74)0.38 (0.09--1.59) Category 37141.08 (0.31--3.83)1.23 (0.22--6.78)1.62 (0.20--13.3)7140.64 (0.21--1.94)0.32 (0.05--1.95)0.30 (0.05--1.84) Category 4481.09 (0.26--4.55)0.83 (0.12--5.72)0.96 (0.05--17.3)4230.21 (0.06--0.74)0.08 (0.01--0.59)0.12 (0.01--0.94)*P* ~trend~0.9530.8600.9190.0130.0160.047*MIP-1α* macrophage inflammatory protein-1 alpha, *MIP-1β* macrophage inflammatory protein-1 beta, *NPC* nasopharyngeal carcinoma, *OR*~*1*~ odds ratio computed using logistic regression adjusted for gender and age, *OR*~*2*~ computed using logistic regression adjusted for gender, age, and anti-Epstein-Barr virus nuclear antigen-1 immunoglobulin A antibody (EBNA1/IgA), *OR*~*3*~ computed using logistic regression adjusted for gender, age, salted fish consumption, family history, and EBNA1/IgA, *CI* confidence interval, *Category 1, 2, 3, and 4* markers were categorized into four groups based on the quartiles among controls, *P*~*trend*~ computed using Wald statistic of regression model parameters for marker intracategory medians modeled as a continuous variable^a^Samples were excluded from the analysis process for the corresponding marker if the marker serum level of each sample exceeded three times the quartile range above the median

Interaction analysis of MIP-1α, MIP-1β, and EBV status with the risk of NPC {#Sec14}
---------------------------------------------------------------------------

As EBV infection may influence the level of cytokines in the body, an interaction analysis was further conducted between MIP-1α, MIP-1β, and EBNA1/IgA. MIP-1α and MIP-1β levels were divided into high and low groups based on the median values of control groups, and the EBV status was divided to seronegative \[EBV(−)\] or seropositive \[EBV(+)\] according to the presence of EBNA1/IgA. The results show that, in the nested case--control study, the OR increased significantly among EBV(+) participants with low MIP-1α (OR = 86.12, 95% CI = 10.58--701.03) or MIP-1β (OR = 115.44, 95% CI = 13.92--957.73) levels, but no statistically significant interaction between these levels was observed (*P* values of 0.134 and 0.211, respectively). Further, the associations remained statistically significant among case patients who were diagnosed more than 1 year after blood collection (MIP-1α: OR = 66, 95% CI 7.19--606.29; MIP-1β: OR = 113.75, 95% CI = 12.61--1114) (Fig. [1](#Fig1){ref-type="fig"}). In the case--control study, low MIP-1α and MIP-1β serum levels in EBV seropositive individuals also showed a higher risk of NPC development (MIP-1α: OR = 16.28, 95% CI = 7.11--37.23; MIP-1β: OR = 12.86, 95% CI = 5.9--28.05).Fig. 1Association of serum macrophage inflammatory protein (MIP)-1α and MIP-1β levels and Epstein--Barr virus (EBV) status with the risk of nasopharyngeal carcinoma (NPC). **a** The case--control study; **b** the nested case--control study. High levels (HL) and low levels (LL) of MIP-1α and MIP-1β in patients with NPC were classified based on the median value among control subjects; EBV(−), seronegative for EBV nuclear antigen-1 immunoglobulin A (EBNA1/IgA); EBV(+), seropositive for EBNA1/IgA. Odds ratios (ORs) and 95% confidence intervals (CIs) were computed using conditional logistic regression adjusted for gender and age. Vertical dashed lines represent an OR of 1.0. Solid black circles represent the ORs, and solid horizontal bars represent the 95% CIs

Correlations between serum levels of MIP-1α, MIP-1β, and other cytokines in the controls of the case--control study and the nested case--control study {#Sec15}
------------------------------------------------------------------------------------------------------------------------------------------------------

The correlations between serum levels of MIP-1α, MIP-1β, and other cytokines were explored among the control subjects in the case--control study and nested case--control study. We found a positive correlation between MIP-1α and MIP-1β levels in both studies (Spearman's correlation coefficient \[ρ\] = 0.51, *P *\< 0.001 in the case--control study; ρ = 0.74, *P *\< 0.001 in the nested case--control study) (Fig. [2](#Fig2){ref-type="fig"}). In addition, there were also statistically significant correlations between IL-8, eotaxin, and MCP-1 levels with the levels of these two markers among control subjects both in the case--control study and in the nested case--control study, with ρ values ranging from 0.18 to 0.63 (all *P *\< 0.05) (Table [5](#Tab5){ref-type="table"}).Fig. 2Macrophage inflammatory protein (MIP)-1α and MIP-1β serum level correlations among control subjects in case--control and nested case--control studies. **a** Hospital-based case--control study; **b** nested case--control study based on the NPC Screening Trial in Sihui. *MIP* macrophage inflammatory protein, *ρ* Spearman's correlation coefficient Table 5The relationship between macrophage inflammatory protein (MIP)-1α or MIP-1β and other cytokinesMarkerMIP-1αMIP-1βCase--control studyNested case--control studyCase--control studyNested case--control studyρ*P*ρ*P*ρ*P*ρ*P*EGF0.290.0700.070.4470.250.0030.020.798Eotaxin0.29\< 0.0010.250.0070.240.0030.220.018GCSF0.39\< 0.0010.060.5440.39\< 0.001− 0.060.544Fractalkine0.240.0040.050.6360.37\< 0.0010.150.134IFN-γ0.380.0080.090.3160.220.0080.110.243GRO0.210.0120.060.5230.260.0020.060.523MDC0.33\< 0.0010.010.9220.260.0020.030.778IL-1α0.160.07− 0.010.8880.190.03− 0.080.394IL-70.270.0010.080.4110.30\< 0.001− 0.0150.875IL-80.47\< 0.0010.63\< 0.0010.30\< 0.0010.49\< 0.001MCP-10.200.0140.190.0350.090.2800.180.048VEGF0.200.0170.090.3480.37\< 0.0010.130.165*ρ* Spearman's correlation coefficient, *MIP-1α* macrophage inflammatory protein-1 alpha, *MIP-1β* macrophage inflammatory protein-1 beta, *EGF* epidermal growth factor, *GCSF* granulocyte colony-stimulating factor, *IFN-γ* interferon gamma, *GRO* growth-regulated oncogene, *MDC* macrophage-derived chemokine, *IL-1α* interleukin-1 alpha, *IL-7* interleukin-7, *IL-8* interleukin-8, *MCP-1* monocyte chemotactic protein-1, *VEGF* vascular endothelial growth factor

Discussion {#Sec16}
==========

Here, we examined the relationship between circulating inflammatory cytokine markers and NPC using a multiplexed immunobead platform in two independent studies. Our results reveal the potential association of decreased MIP-1α and MIP-1β levels with the prospective risk of NPC development in southern China. The association was independent of EBV infection, and the risk increased remarkably with decreasing MIP-1α and MIP-1β levels. Moreover, this relationship remained in the subset of serum samples that were collected more than 1 year before NPC onset. The present findings are also consistent with the previously reported evidence that MIP-1α and MIP-1β levels are inversely related to head and neck squamous cell cancers \[[@CR33]\].

MIP-1α and MIP-1β are two important and closely related members of the MIP-1 CC chemokine subfamily. They are produced by a variety of lymphocytes, including monocytes, macrophages, activated T cells, and B cells \[[@CR34]\]. Additionally, these chemokines play major roles in the recruitment of leukocytes to infection sites \[[@CR35]\], the delivery of interferon (IFN) to mediate protective responses against several kinds of virus infections \[[@CR36], [@CR37]\], and the induction of antitumor responses \[[@CR35]\]. It was reported that MIP-1β can also inhibit the entry and replication of viruses through chemokine receptor binding \[[@CR34]\]. Therefore, we speculate that the mechanisms underlying the link between decreased MIP-1α and MIP-1β levels and the risk of developing NPC are related to the dysfunction of anti-EBV immunity and anti-tumor immunity.

Normally, EBV is in a latent status in B lymphocytes under strict monitoring by the immune system, although the virus may be periodically reactivated in response to environmental stress, such as smoking \[[@CR38]\] or the consumption of Cantonese-style salted fish \[[@CR39]\] or Chinese herbs \[[@CR40]\]. With the defective immunity induced by relatively low MIP-1α or MIP-1β levels, lymphocytes may not move into tissues with EBV replication and become appropriately activated, thus promoting more EBV shedding in the nasopharynx and inducing oncogenic transformation of the infected nasopharyngeal epithelium. As EBV infection is an important risk factor for NPC and can lead to chronic inflammation, it is possible that MIP-1α or MIP-1β may interact with EBV to increase the risk of NPC. We conducted a stratification analysis to assess this possibility, and the results revealed that the OR for NPC development increased prominently in subjects with EBV seropositivity who had a low level of MIP-1α or MIP-1β; however, no significant interaction was found, likely due to the relatively small number of samples in this study.

Statistically significant associations were observed between NPC and the levels of several inflammatory cytokines, i.e., EGF, GCSF, fractalkine, GRO, IL-1α, IL-7, and MCP-1, in the case--control study. These findings for EGF, GCSF, GRO, and MCP-1 are consistent with those from previous case--control studies of other cancers, such as gastric cancer \[[@CR41], [@CR42]\], breast cancer \[[@CR43], [@CR44]\], and renal cell carcinoma \[[@CR45]\]. The associations of these inflammatory cytokines with cancer suggest that changes to a cluster of inflammatory cytokines may be caused by the tumor and could be related to patients' progress. In contrast to our results, one paper reported that NPC patients in Sichuan, China, a non-NPC endemic area, had elevated IL-1α levels in circulation \[[@CR46]\]. The different characteristics of the participants in these two studies, including the different race, pathological types, and EBV infection status, might have affected the IL-1α levels. Thus, additional studies need to be conducted to verify the relationship between IL-1α and NPC in endemic areas.

Several inflammation markers associated with NPC that were reported by other studies were not found in the present study, either because they were not contained in the cytokine panel (such as C-reactive protein) or because they had a lower sensitivity in this platform (such as IL-6 and IL-10) \[[@CR47], [@CR48]\]. The main reason for the relatively low detection sensitivity for some markers could be interference from other markers in the platform. Another study using the same Millipore 39-plex panel also showed that 17 markers (43%) had low detection sensitivity \[[@CR30]\].

The present study has several strengths. The association of the maximum number of immune markers with the risk of NPC was evaluated in this study. The prospective design of this study minimized the potential bias as a result of disease-induced effects. Moreover, the high validity, reproducibility, and stability of the cytokine testing using a multiplex immunobead platform attributed to good assay performances; specifically, the ICCs of cytokines were all \> 0.9, and the CVs of the detectable cytokine markers were all \< 0.28.

The study also had some limitations. The immune mechanism disturbance with decreased circulating MIP-1α and MIP-1β levels in the preclinical NPC patients may not reflect the levels of these cytokines in the inflammation lesion site that are directly relevant to NPC development (e.g., EBV-mediated inflammation or nasopharyngeal mucosa-associated inflammation). The relatively small sample size in our study restricted its detection of significant associations between the two markers and NPC development when a Bonferroni correction was used to adjust the probability values (*P*~*ad*~ = *P*/N = 0.05/14 = 0.0036). However, it is unlikely that the MIP-1α and MIP-1β levels decreased in NPC by chance, given that they remained significantly associated with NPC in an independent nested case--control study (Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Conclusions {#Sec17}
===========

In conclusion, this study found that serum MIP-1α and MIP-1β levels were inversely correlated with the risk of NPC, suggesting an etiologic role for defective antivirus and antitumor immunity in NPC carcinogenesis. Additional investigations are needed to elucidate the biologic mechanisms underlying this association.

Additional file
===============

 {#Sec18}

**Additional file 1: Table S1.** Performance characteristics of measurement for 33 inflammation markers.

NPC

:   nasopharyngeal carcinoma

OR

:   odds ratio

CI

:   confidence interval

EBV

:   Epstein--Barr virus

EGF

:   epidermal growth factor

GCSF

:   granulocyte colony-stimulating factor

IFN-γ

:   interferon gamma

GRO

:   growth-regulated oncogene

MDC

:   macrophage-derived chemokine

IL-1α

:   interleukin-1 alpha

IL-7

:   interleukin-7

IL-8

:   interleukin-8

MCP-1

:   monocyte chemotactic protein-1

MIP-1α

:   macrophage inflammatory protein-1 alpha

MIP-1β

:   macrophage inflammatory protein-1 beta

VEGF

:   vascular endothelial growth factor

CV

:   coefficients of variation

ICC

:   intra-class correlation coefficient
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